CYTK
Cytokinetics Inc.
Nasdaq · usd
Cytokinetics Inc. (CYTK) trades at $61.03 (-0.33%) as of 2:22:16 PM EDT on Oct 26, 2026, -5.64% over the past month. Market cap is $8.51B, with 8.4 days to cover in short interest.
Stock performance
How Cytokinetics Inc. (CYTK) stock has performed from one day to one year, with its 52-week range.
- 1D
- -0.36%
- 1W
- -2.62%
- 1M
- -5.64%
- YTD
- -3.98%
- 1Y
- +1.38%
- 52-wk range
- $57.83 – $88.31
Key statistics
Today's trading snapshot for CYTK: day range, open, previous close, volume and market cap.
- Day range
- $60.87 – $61.89
- Open
- $61.45
- Prev close
- $61.23
- Volume
- 308.49K
- Market cap
- $8.51B
- Shares out
- 124.43M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Cytokinetics Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 125.79
- P/B
- -49.07
- P/FCF
- —
- ROE
- 515.3%
- ROA
- -46.5%
- Debt/Equity
- -6.61
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Cytokinetics Inc. has disclosed to the SEC on Form 8-K.
- Clinical trial resultsAug 28, 2026
Cytokinetics, Incorporated issued a press release announcing its presentation of the full results of ACACIA-HCM at the European Society of Cardiology (ESC) Congress 2026 and published in the New England Journal of Medicine.
- Material litigationAug 13, 2026
On August 13, 2026, Cytokinetics, Incorporated (the "Company") filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory judgment that the Company does not infringe U.S. Patent No. 12,616,697 (the "'697 patent") and that the claims of the '697 patent are invalid.
- Equity compensation grantMay 27, 2026
The stockholders approved the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan by 1,000,000 shares of common stock.
- Public offeringMay 8, 2026
On May 6, 2026, Cytokinetics, Incorporated (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the public offering, issuance and sale (the "Offering") of 9,859,155 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), at a public offering price of $71.00 per share of Common Stock.
- Investor presentationMay 5, 2026
On May 5, 2026, Cytokinetics, Incorporated released its current corporate presentation, which is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Dividend history and stock splits
Cytokinetics Inc.'s recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-6Jun 25, 2013
CYTK short interest
How heavily CYTK is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 8.4
- Short interest
- 19.33M
- Avg volume
- 2.31M
As of · reported to FINRA twice monthly.
CYTK news
The latest news and headlines about Cytokinetics Inc. (CYTK).
- Cytokinetics to Announce Third Quarter Results on November 4, 2026positiveGlobeNewswire Inc.· Oct 21, 2026
- Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?positiveThe Motley Fool· Oct 20, 2026
- Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026positiveGlobeNewswire Inc.· Oct 2, 2026
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?positiveThe Motley Fool· Sep 18, 2026
- Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?positiveZacks Investment Research· Sep 4, 2026
Frequently asked questions
What is the Cytokinetics Inc. (CYTK) stock price today?
Cytokinetics Inc. (CYTK) is trading at $61.03 (-0.33% on the day) as of 2:22:16 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Cytokinetics Inc.?
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised…
What is the short interest in CYTK?
As of Sep 30, 2026, CYTK has 19.33M shares short and 8.4 days to cover.
What exchange is CYTK listed on?
Cytokinetics Inc. (CYTK) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of CYTK with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a CYTK analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.